Search
Secukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigationalSecukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque … [A249805] It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.
Gallium citrate Ga-67
go.drugbank.com/drugs/DB06784ApprovedGallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metasta...
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.
Synonyms: -trimethyl-3,5-bis(trifluoromethyl)-, 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamidersPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnProstate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine...
Zorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
LNP-nCoVsaRNA Vaccine
go.drugbank.com/drugs/DB15799ExperimentalLNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.
Cefepime
go.drugbank.com/drugs/DB01413ApprovedInvestigationalCefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. … [A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.
Ubidecarenone
go.drugbank.com/drugs/DB09270ApprovedInvestigationalNutraceutical[L1062] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease.